NCT07148128
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT07148128
Title Phase 1/2a Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of WEF-001 as Monotherapy in Advanced KRAS-Mutant Solid Tumours.
Recruitment Recruiting
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Auricula Biosciences Inc.
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA | GBR


No variant requirements are available.